Navigation Links
Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly

LONDON, November 13, 2013 /PRNewswire/ --

First-in-class antipsychotic therapy for Schizophrenia and Bipolar Disorders

Zysis, a private pharmaceutical company optimising therapies for disorders of the Central Nervous System, today announced that the United States Patent and Trademark Office has granted U.S. patent 8,575,172 covering its Phase II ready Long Acting Oral Aripiprazole Once Weekly (LAO Aripiprazole OW) product, a first-in-class antipsychotic therapy for orally dosed relapse prevention in patients suffering from Schizophrenia and Bipolar Disorders.

LAO Aripiprazole OW with medically supervised dosing is an alternative option to Long Acting Injectables (LAI) in the rapidly expanding market for prevention of psychotic relapse.  Non-adherence rates are extremely high with schizophrenia therapy; around 75% of patients are non-adherent within two years of being discharged from hospital[1], the consequences of which are medically and economically severe with 69% of patients with poor adherence suffering a relapse[2].

Peter Cozens, Chairman of Zysis said: "LAO Aripiprazole OW is a promising, cost effective option in the treatment of Schizophrenia, Schizoaffective Disorder and Bipolar Disorders for the large number of patients struggling with adherence.  We are very pleased to receive the U.S. Patent. This is an important event for Zysis. LAO Aripiprazole OW represents a breakthrough treatment providing another option to address unmet patient needs while improving their quality of life." 

Dr Robert Millet, Distinguished Fellow of the American Psychiatric Association and renowned US expert in long-acting therapies for the treatment of psychotic symptoms at Carolina Behavioral Care added: "I see adherence as a major factor in schizophrenia treatment today and this once weekly therapy has the potential to provide a very real benefit in relapse prevention for those patients struggling to comply to daily oral treatment but who are not ready for monthly injectable therapy"

Professor Allan Young, Professor of Psychiatry at Imperial College London added: "Adherence is a big issue and contributes significantly to poorer outcomes in schizophrenia and bipolar disorder. The potential market for a weekly oral antipsychotic would likely be significant, and an accompanying "compliance" package would be welcomed by the community."

The recently granted U.S. Patent covers the treatment of psychotic conditions with orally-delivered formulations of aripiprazole that provide for sustained-release, once-weekly therapy. Patents have already been granted in Europe, Israel and Australia and applications are pending in Canada, South Korea and Japan. The new patent and related applications are all solely owned by Zysis.


1. Weiden PJ et al. Psychiatr Serv, 1995; 46: 1049-1054

2. Morken G et al. BMC Psychiatry, 2008;  8: 32-38

Notes to editors:

About Zysis

Zysis is a privately-owned specialty pharmaceutical company optimising therapies for disorders of the central nervous system (CNS).  Zysis has reformulated aripiprazole, an effective antipsychotic molecule, to provide a patent-protected, sustained-release, once-weekly maintenance phase therapy in oral tablet form to improve clinical outcomes in schizophrenia and bipolar disorder therapy. Formulation development / initial Phase I studies have been successfully completed and the Phase II clinical programme has been established.  Zysis is currently seeking funding to progress the phase II study either through licensing or by raising finance.

About LAO Aripiprazole Once Weekly

LAO Aripiprazole Once Weekly with medically supervised dosing is intended to reduce relapse rate in the population of schizophrenic and bipolar patients who require approaches to increase adherence but who are not ready yet for the highly invasive and extremely expensive option of the LAIs.  The ability to achieve oral once weekly dosing for aripiprazole comes from a combination of sustained release technologies; long drug plasma half-life; and the very slow disassociation of drug from the D2 receptors in the brain which appears to be unique to this anti-psychotic.   LAO and LAI products are highly synergistic in the market and provide a broader range of options for use in improving adherence, dependent on severity of the condition and relapse history of the patients. 

For further information, please contact:

Dr Peter Cozens, Chairman
Tel: +44-1798-831278

Hume Brophy
Mary Clark, Hollie Vile, Supriya Mathur
Tel: +44-20-3440-5653

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
2. Dr. Rongxiang Xu Receives the Prestigious Scroll Award from Los Angeles County Government
3. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
4. Johns Hopkins Receives Prestigious ABET Accreditation for Its Part-time Master’s Degree in Systems Engineering
5. Ameritox Receives Accreditation from College of American Pathologists
6. Serial Entrepreneur, Rudy Mazzocchi, Receives Global Business Recognition Award as the 2013 Entrepreneur of the Year
7. Histogen’s Composition for Hair Growth Receives US Patent
8. Profound Medical Receives IDE Approval from FDA to Conduct TULSA Clinical Trial for New Treatment for Localized Prostate Cancer
9. Nasseo’s TiArray™ Dental Implant System Receives FDA Approval
10. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
11. BioLineRxs BL-8040 Receives Orphan Drug Designation for Treatment of AML
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):